This is to inform you that on October 23, 2015 the Morbidity and Mortality Weekly Report (MMWR) published the June 24, 2015 Advisory Committee on Immunization Practices (ACIP) recommendation stating a MenB vaccination series may be administered to individuals between the ages of 16 through 23.1
To view the October 23, 2015 MMWR publication, click here.
The recommendation is as follows:
Advisory Committee on Immunization Practices (ACIP) recommends that a MenB vaccine series may be administered to adolescents and young adults aged 16 through 23 years to provide short-term protection against most strains of MenB disease. The preferred age for MenB vaccination is 16 through 18 years. The recommendation is labeled as Category B meaning that individual clinical decision making is recommended.
It is important to note that The Affordable Care Act ensures insurance coverage for all ACIP-recommended vaccinations including Category B ACIP recommendations. Healthcare providers should contact their individual plan to determine specific coverage and reimbursement requirements and adoption timeframes.2 MenB vaccines are available through the Vaccines for Children program.3
This recommendation is in addition to the existing Category A MenB recommendation for individuals aged ≥ 10 years at increased risk for meningococcal disease, published in the June 12, 2015 edition of the MMWR (click here to view).
Please reach out to your local Pfizer Vaccine Specialist.